Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disease and a composite endpoint could be an indicator of treatment effect on disease worsening. This post-hoc analysis assessed whether indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily reduced the risk of clinically...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Respir Res
Autors principals: Anzueto, Antonio R., Kostikas, Konstantinos, Mezzi, Karen, Shen, Steven, Larbig, Michael, Patalano, Francesco, Fogel, Robert, Banerji, Donald, Wedzicha, Jadwiga A.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6011394/
https://ncbi.nlm.nih.gov/pubmed/29925383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0830-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars